Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 binding to PD-L1/2 on tumor and inflammatory cells....
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/11/11/1235 |
| _version_ | 1827676224956137472 |
|---|---|
| author | Valerio Nardone Rocco Giannicola Diana Giannarelli Rita Emilena Saladino Domenico Azzarello Caterina Romeo Giovanna Bianco Maria Rosaria Rizzo Irene Di Meo Antonio Nesci Pierpaolo Pastina Antonia Consuelo Falzea Daniele Caracciolo Alfonso Reginelli Michele Caraglia Amalia Luce Luciano Mutti Antonio Giordano Salvatore Cappabianca Luigi Pirtoli Vito Barbieri Pierfrancesco Tassone Pierosandro Tagliaferri Pierpaolo Correale |
| author_facet | Valerio Nardone Rocco Giannicola Diana Giannarelli Rita Emilena Saladino Domenico Azzarello Caterina Romeo Giovanna Bianco Maria Rosaria Rizzo Irene Di Meo Antonio Nesci Pierpaolo Pastina Antonia Consuelo Falzea Daniele Caracciolo Alfonso Reginelli Michele Caraglia Amalia Luce Luciano Mutti Antonio Giordano Salvatore Cappabianca Luigi Pirtoli Vito Barbieri Pierfrancesco Tassone Pierosandro Tagliaferri Pierpaolo Correale |
| author_sort | Valerio Nardone |
| collection | DOAJ |
| description | An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 binding to PD-L1/2 on tumor and inflammatory cells. It has been speculated that a chronic status of systemic inflammation as well as the immunosenescence physiologically occurring in elderly patients may affect the efficacy of the treatment and the occurrence of irAEs. We performed a multi-institutional retrospective study aimed at evaluating the effects of these mAbs (nivolumab or atezolizumab) in 117 mNSCLC patients younger (90 cases) and older (27 cases) than 75 years in correlation with multiple inflammatory parameters (NLR, CRP, ESR, LDH and PCT). No differences were observed when the cohorts were compared in terms of the frequency of PFS, OS, inflammatory markers and immune-related adverse events (irAEs). Similarly, the occurrence of irAEs was strictly correlated with a prolonged OS survival in both groups. On the contrary, a negative correlation between the high baseline levels of inflammatory markers and OS could be demonstrated in the younger cohort only. Overall, PD-1/PD-L1-blocking mAbs were equally effective in young and elderly mNSCLC patients; however, the detrimental influence of a systemic inflammation at the baseline was only observed in young patients, suggesting different aging-related inflammation immunoregulative effects. |
| first_indexed | 2024-03-10T05:20:40Z |
| format | Article |
| id | doaj.art-62314baa55cc425bb501c2b7b1efcaef |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T05:20:40Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-62314baa55cc425bb501c2b7b1efcaef2023-11-23T00:04:52ZengMDPI AGLife2075-17292021-11-011111123510.3390/life11111235Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional AnalysisValerio Nardone0Rocco Giannicola1Diana Giannarelli2Rita Emilena Saladino3Domenico Azzarello4Caterina Romeo5Giovanna Bianco6Maria Rosaria Rizzo7Irene Di Meo8Antonio Nesci9Pierpaolo Pastina10Antonia Consuelo Falzea11Daniele Caracciolo12Alfonso Reginelli13Michele Caraglia14Amalia Luce15Luciano Mutti16Antonio Giordano17Salvatore Cappabianca18Luigi Pirtoli19Vito Barbieri20Pierfrancesco Tassone21Pierosandro Tagliaferri22Pierpaolo Correale23Department of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyMedical Oncology Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyBiostatistical Unit, National Cancer Institute “Regina Elena”, IRCCS, 00161 Rome, ItalyTissue typing Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyMedical Oncology Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyMedical Oncology Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyMedical Oncology Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyDepartment of Advanced Medical and Surgical Sciences, University of Campania “Luigi Vanvitelli”, 80138 Naples, ItalyUnit of Pharmacy, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalySection of Radiation Oncology, Medical School, University of Siena, 53100 Siena, ItalyMedical Oncology Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyMedical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalySbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USASbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USADepartment of Precision Medicine, University of Campania “L. Vanvitelli”, 80138 Naples, ItalySbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA 19122, USAMedical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, ItalyMedical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, ItalyMedical and Translational Oncology Unit, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, ItalyMedical Oncology Unit, Grand Metropolitan Hospital “Bianchi-Melacrino-Morelli”, 89124 Reggio Calabria, ItalyAn immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 binding to PD-L1/2 on tumor and inflammatory cells. It has been speculated that a chronic status of systemic inflammation as well as the immunosenescence physiologically occurring in elderly patients may affect the efficacy of the treatment and the occurrence of irAEs. We performed a multi-institutional retrospective study aimed at evaluating the effects of these mAbs (nivolumab or atezolizumab) in 117 mNSCLC patients younger (90 cases) and older (27 cases) than 75 years in correlation with multiple inflammatory parameters (NLR, CRP, ESR, LDH and PCT). No differences were observed when the cohorts were compared in terms of the frequency of PFS, OS, inflammatory markers and immune-related adverse events (irAEs). Similarly, the occurrence of irAEs was strictly correlated with a prolonged OS survival in both groups. On the contrary, a negative correlation between the high baseline levels of inflammatory markers and OS could be demonstrated in the younger cohort only. Overall, PD-1/PD-L1-blocking mAbs were equally effective in young and elderly mNSCLC patients; however, the detrimental influence of a systemic inflammation at the baseline was only observed in young patients, suggesting different aging-related inflammation immunoregulative effects.https://www.mdpi.com/2075-1729/11/11/1235immune checkpoint blockademetastatic non-small-cell lung cancerreal-world evidence studyageinflammatory markersimmunotherapy |
| spellingShingle | Valerio Nardone Rocco Giannicola Diana Giannarelli Rita Emilena Saladino Domenico Azzarello Caterina Romeo Giovanna Bianco Maria Rosaria Rizzo Irene Di Meo Antonio Nesci Pierpaolo Pastina Antonia Consuelo Falzea Daniele Caracciolo Alfonso Reginelli Michele Caraglia Amalia Luce Luciano Mutti Antonio Giordano Salvatore Cappabianca Luigi Pirtoli Vito Barbieri Pierfrancesco Tassone Pierosandro Tagliaferri Pierpaolo Correale Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis Life immune checkpoint blockade metastatic non-small-cell lung cancer real-world evidence study age inflammatory markers immunotherapy |
| title | Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_full | Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_fullStr | Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_full_unstemmed | Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_short | Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_sort | distinctive role of the systemic inflammatory profile in non small cell lung cancer younger and elderly patients treated with a pd 1 immune checkpoint blockade a real world retrospective multi institutional analysis |
| topic | immune checkpoint blockade metastatic non-small-cell lung cancer real-world evidence study age inflammatory markers immunotherapy |
| url | https://www.mdpi.com/2075-1729/11/11/1235 |
| work_keys_str_mv | AT valerionardone distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT roccogiannicola distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT dianagiannarelli distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT ritaemilenasaladino distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT domenicoazzarello distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT caterinaromeo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT giovannabianco distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT mariarosariarizzo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT irenedimeo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT antonionesci distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierpaolopastina distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT antoniaconsuelofalzea distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT danielecaracciolo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT alfonsoreginelli distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT michelecaraglia distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT amalialuce distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT lucianomutti distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT antoniogiordano distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT salvatorecappabianca distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT luigipirtoli distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT vitobarbieri distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierfrancescotassone distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierosandrotagliaferri distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierpaolocorreale distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis |